



Universiteit
Leiden
The Netherlands

Circulating gut-associated antigens of *Schistosoma mansoni* : biological, immunological, and molecular aspects

Dam, G.J. van

Citation

Dam, G. J. van. (1995, February 9). *Circulating gut-associated antigens of Schistosoma mansoni : biological, immunological, and molecular aspects*. Retrieved from <https://hdl.handle.net/1887/41317>

Version: Not Applicable (or Unknown)

License:

Downloaded from: <https://hdl.handle.net/1887/41317>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/41317> holds various files of this Leiden University dissertation.

Author: Dam, G.J. van

Title: Circulating gut-associated antigens of *Schistosoma mansoni* : biological, immunological, and molecular aspects

Issue Date: 1995-02-09

Chapter 1

***Schistosoma* gut-associated antigens**

Chapter 1

Schistosoma gut-associated antigens

Schistosomes are blood-dwelling flukes belonging to the class Trematoda, but differ from all other trematodes in that the sexes are separate (Fig. 1). The parasites have a sexual reproduction phase in the definitive host, and an asexual reproduction phase in a snail intermediate host (Fig. 2). Definitive hosts are *e.g.* humans, cattle, rodents, primates, or dogs, depending on the *Schistosoma* species [9]. In the laboratory, hamsters and mice are often used both as definitive hosts for maintaining the parasite-cycle and as experimental animals. The *Schistosoma* species which are most important in human schistosomiasis are *S. mansoni*, *S. japonicum*, and *S. haematobium*.




Figure 1. Paired adult *Schistosoma mansoni* worms. Clearly visible is how the male worm enfolds the female within its gynaephoric canal. Magnification approximately 40 X. (courtesy of Dr. Ming M. Wong, U.C. Davis, U.S.A.)




Figure 2. Life cycle of *Schistosoma mansoni* and *Schistosoma haematobium*.
(courtesy of Dr. A.M. Deelder)

The infective parasitic stage, the cercaria, enters the host through the skin, evoking an inflammatory response. In naive hamsters, neutrophils are among the first cells to attack the parasite, followed after a few days by eosinophils [37]. From this stage to about 3 weeks after infection, the parasite, present as a young schistosomulum, is most susceptible to immune damage [11,21,36,78, 79,82,97,132]. Employing a wide range of evasion mechanisms, the developing worm becomes refractory or even invisible to certain parts of the host's defense system. Consequently, the worms persist in the host for an estimated 3–5 years [55,130], although a number of reports indicated much longer times [59,127,129], and recently it has been reported that in some cases even almost 40 years after infection viable eggs were excreted [62]. Among the evasion mechanisms employed by schistosomula and adult worms are: 1. camouflage by acquisition of host antigens [35,58,114]; 2. reduction of surface antigenicity by tegument antigen shedding [49,94]; 3. modulation of the host's immune response by eliciting blocking antibodies [19,51,69]; 4. induction of cellular immunoregulatory mechanisms, e.g. downregulation of host-protective Th1-type response [95,98]; 5. induction of immunosuppressive mechanisms by excretion of specific T cell suppressor factors [2,7,22,23,77]; 6. acquisition of specific complement inhibitory membrane-bound molecules [63,96]; 7. inhibition of the immune effector cell function or lysis of cells which adhere to the parasite surface [28–31,56,102]; and 8. clearance from the surface by sloughing of antibody-antigen complexes or of molecules which are potentially harmful to the parasite [74,109,110,123].

At about 6 weeks post infection (*p.i.*) the adult worm-pairs start to produce eggs, which either penetrate the intestinal wall to be voided in the faeces (*Schistosoma mansoni* and *S. japonicum*) or the bladder wall to leave the body via the urine (*S. haematobium*). However, a considerable proportion of the eggs is not excreted but *e.g.* transported with the blood to the liver where they are retained and induce granuloma formation and subsequent liver-fibrosis [3,34,128]. *S. haematobium* induced pathology involves mainly the bladder and kidney [34,116].

A striking gross observation on the gut of schistosomes is that in healthy, freshly isolated worms the intestinal tract is filled with a dark slurry of partly digested blood. Since the gut is a cul-de-sac, the parasite has to regurgitate at regular intervals, releasing a dark cloud of undigested particulate material including parasite antigens [16,113] (Fig. 3). These relatively abundant excretory antigens may exhibit various functions and characteristics, *e.g.* in immune evasion mechanisms. A number of these antigens, which will be discussed below, can also be detected in the circulation of the host. In this review, most attention will be given to a group of highly glycosylated circulating gut-associated antigens [99].




Figure 3. Anterior portion of male and female schistosome worms showing blood pigments (A) in gut and (B) in regurgitant; (C) detail of female gut at level of vitelline gland. Magnification approximately 50 X (A), 20 X (B), 100 X (C). (photographs taken by Dr. A.W. Senft, reproduced with permission from [113])

Other circulating antigens are found among tegument-associated antigens [38,66,115], egg antigens, *e.g.* released as hatching fluid [60,89,90,103,115] and cercarial antigens [1,61], but these fall outside the scope of this introduction.

Antigens present in the schistosome gut, but which have, so far, not been described as being detectable in the circulation, are proteases like hemoglobinase or cathepsin B [16,17,32,71], phospholipase A2 [105], a 68 kDa antigen which might be a vaccine candidate [13], or glutathione-S-transferases [18,81]. Although the gut proteases themselves have not been demonstrated in the circulation¹, which can be due to rapid degradation or to very low concentrations, a specific and strong antibody response to these antigens has been reported [33,107,108].

After an experimental infection with schistosomes, the first antibodies have been shown to be detectable two to three weeks *p.i.*, using an immunofluorescence assay on adult worm sections [10,46,93,100]. These antibodies were directed against the gut epithelium of the parasite. As the infection progresses, additional fluorescence has been found at the level of the tegumental membrane (4 – 5 weeks *p.i.*) and finally within the parenchyma (5 – 6 weeks *p.i.*) [93,125]. In general, the highest titres are always observed against gut antigens [45,48,53,84,87,93], probably because these antigens are excreted in relatively large quantities into the host circulation [80,131]. Earlier it had been reported that schistosome circulating antigens, detected by immunoelectrophoresis, appeared in the serum of mice 26 days after infection [12], which correlates with the time-point that the antibodies appear. By adsorption of patient serum with purified antigen preparations it has been shown that antibodies against both the circulating anodic antigen (CAA) and the circulating cathodic antigen (CCA) were responsible for the gut-associated immunofluorescence [46]. This finding was partly contrary to earlier observations, in which it had been found that only antibodies specific for CAA were detected in the gut [84]. Later studies showed that 90% of the patient IgM antibodies reactive with the schistosome gut in an immunofluorescence assay could be inhibited by anti-CCA, but not by anti-CAA or anti-cathepsin B (32 kDa) monoclonal antibodies [48], demonstrating the immunodominance of CCA in the IgM immune response against the gut-associated antigens. This inhibition was only slightly lower in more chronic infections. Antibodies to cathepsin B present in the schistosome gut were detectable from week 3 after infection [33] and seemed to increase as the infection progresses (J.P. Rotmans, unpublished observations).

Ultrastructural localization studies using monoclonal antibodies (McAbs) specific for CAA and CCA have shown that the antigens are present in the gut of adult worm, as well as in the primordial gut cells of cercariae and in 3½ week old worms [41,42]. The localization patterns indicated that the antigens may be derived from the rough endoplasmatic reticulum, and transported via the Golgi apparatus and cytoplasmic vesicles to the luminal side of the syncytium where

¹ recently, an ELISA was described in which the *S. japonicum* 31/32 kDa hemoglobinase was detected in the serum of Chinese schistosomiasis patients [76]

they finally may be released into the gut lumen [41,42]. Thus, they exhibit a biosynthesis and transport mechanism similar to that proposed for glycoconjugates associated with the gut epithelium of other trematodes or vertebrates [14,15,75]. Deelder and co-workers described the presence of CAA in epithelial cells lining the schistosome gut from the cercarial stage and onward (as also found by Andrade and Sadigursky (1978) [4]) but never on the schistosome tegument [42,46]. Likewise, CCA was primarily found in the schistosome gut, but not on the tegument. Conflicting results were obtained for CCA with respect to detectability in egg extracts [44,46], but using McAbs in immunoelectrophoresis, and in immunofluorescence and/or in dot-immunobinding assays, it was established that CCA was also present in schistosome eggs (Chapter 3, and [48]). Partly contrary to these findings, Barsoum *et al.* (1992) [8], showed the binding of a CCA-specific McAb to the schistosome tegument, although the major reactivity was to the gut epithelial cells.

The early antibody response to gut-associated antigens in comparison to tegument or other schistosome antigens might be the result of very immunodominant epitopes on the gut-associated antigens, or of the relatively large amounts of antigens which are released into the host circulation early in development of the parasite. The high excretion rate of gut-associated antigens probably means that the worms exhibit high metabolic activity starting early in life.

Aside from indirect demonstration by the antibody response, the *circulating* antigens themselves are detectable in the *circulation* of the host. A circulating antigen in the plasma of mice or hamsters heavily infected with *Schistosoma mansoni* was first described by Berggren and Weller (1967) [12]. An anodic precipitate was observed by immunoelectrophoresis (Fig. 4), which was correlated with worm burden and duration of infection. The antigen of non-host origin was detected from day 26 *p.i.* onwards in mice infected with more than 500 cercariae [12], and from day 21 *p.i.* onwards in hamsters infected with 1100 cercariae [57]. Gold *et al.* (1969) [57] demonstrated that the antigen could also be found in urine, although in small quantities. Initial characterizations showed that this antigen was heat-stable, dialyzable with a MW < 10 kDa, and had an UV absorption maximum at 260 nm. However, enzyme incubations indicated that it was not DNA or RNA [57]. Further characterizations of this antigen, which was later named the gut-associated proteoglycan GASP [86] or the circulating anodic antigen CAA [44]¹, were carried out by Nash *et al.* (1974, 1977) [86,88] and by Deelder *et al.* (1976, 1980) [44,46]. Results are summarized in Table 1.

¹ Although a recommendation has been made to rename the antigen GASCAP [85], CAA is now widely used to denote this antigen, and throughout this thesis the acronym CAA will be used.

Table 1. Characteristics of circulating anodic antigen

Characteristics	Reference
molecular properties	
5% ^a (w/w) amino acids:	
rich in Glycine, low proportion of Phenylalanine and Tyrosine	[86]
41% ^a (w/w) carbohydrates:	
GalNAc : Gal : GlcNAc : Man : GlcA = 17.2 : 2 : 1.9 : 0.4 : 16.1	[86]
physico-chemical properties	
negatively charged	[86]
MW by ultracentrifugation < 10 kDa	[57]
gelfiltration 50 – 300 kDa	[46,88]
polyacrylamide gel electrophoresis > 800 kDa	[44]
ultrafiltration > 100 kDa	[88]
ultracentrifugation of immune complexes 70 kDa	[67]
immuno-electrophoretic motility: highly anodic	[12,44,88]
resistant to 30 min boiling	[88]
7.5% Trichloroacetic acid	[88]
pronase, trypsin	[88]
alkaline phosphatase, DNase, RNase, α -amylase	[88]
destroyed by periodate	[88]
no absorption peaks at 280 nm or at 260 nm	[86]
immunogenic properties	
specific antibodies demonstrated 3 – 4 weeks after infection	[46,84]
IgM levels higher than IgG levels	[46,87]
biological properties	
<i>Schistosoma</i> genus-specific antigen, demonstrated in <i>Schistosoma mansoni</i> , <i>S. haematobium</i> , <i>S. japonicum</i> , <i>S. intercalatum</i> , (<i>S. curassoni</i> , <i>S. bovis</i> , <i>S. mattheei</i>) ^b	[40,73,88]
detected in host's serum and/or urine	[44,57,88]
localization	
in the adult worm and the developing schistosomulum:	
primarily in epithelial cells of the gut	[46,83]
gut lumen in lysosome-like bodies, associated with host leukocytes	[42]
intracellularly in Golgi apparatus and cytoplasmic vesicles	[42]
in cercariae: primordial oesophagus	[4]
in cytoplasm and surface coat of gut epithelium	[42]
also found in the host in:	
glomerulus of kidney	[46,52]
Kupffer cells	[46,52]
macrophages in spleen	[52]

^a amino acids and carbohydrates together makes 46% of the total weight of material analyzed; material resistant to hydrolysis or incompletely derivatized, salts and water may account for the remaining weight

^b Deelder, *et al.*, unpublished observations

Table 2. Characteristics of circulating cathodic antigen

Characteristics	Reference
molecular properties	
37% ^a (w/w) amino acids: rich in Glycine, Serine and Threonine, low proportion of Phenylalanine and Tyrosine	[27]
63% ^a (w/w) carbohydrates: GalNAc : Gal : GlcNAc : Fuc : Man = 1 : 6.6 : 2.9 : 3.0 : 1.6	[27]
physico-chemical properties	
neutral or slightly positively charged	[27,46]
MW by gel filtration 10 – 300 kDa	[27,46]
polyacrylamide gel electrophoresis > 400 kDa	[27]
ultracentrifugation of immune complexes 40 kDa	[68]
immuno-electrophoretic motility: cathodic	[25,27,46]
resistant to 120 min boiling	[24]
10% Trichloroacetic acid	[25]
protease	[25]
ribonuclease, neuraminidase, amylase	[25]
destroyed by periodate	[25]
immunogenic properties	
specific antibodies demonstrated 3 – 4 weeks after infection	[46,47]
IgM levels higher than IgG levels	[46]
biological properties	
<i>Schistosoma</i> genus-specific antigen, demonstrated in <i>Schistosoma mansoni</i> , <i>S. haematobium</i> , <i>S. japonicum</i> , <i>S. intercalatum</i> , (<i>S. curassoni</i> , <i>S. bovis</i> , <i>S. mattheer</i>) ^b	[25,46,73,101]
detected in host's serum, urine, or milk	[25,39,44,111]
localization	
in the adult worm and the developing schistosomulum: primarily localized in epithelial cells of the gut	[27,46]
in gut lumen in lysosome-like bodies	[41]
intracellularly in Golgi apparatus and cytoplasmic vesicles	[42]
male tegument	[8]
in eggs: contradictory results	[44,46]
in miracidia: not found	[41]
in cercariae: in cytoplasm and surface coat of gut epithelium	[41]
also found in the host in: glomerulus of kidney	[41]
Kupffer cells	[43,46]
macrophages in spleen	[43]

^a percentages given by the authors; the percentage amino acids was probably obtained by subtracting from 100% the total weight of sugars (63%) found by methylation analysis

^b Deelder, *et al.*, unpublished observations




Figure 4. Immunoelectropherogram of an anti-CAA (upper lane) and an anti-CCA (lower lane) McAb against AWA-TCA.

In the urine of schistosomiasis patients, Carlier *et al.* (1975) [24] have found a second circulating antigen, 'M antigen', which in immunoelectrophoresis appeared neutral or slightly cathodic (Fig. 4) [25,27]. The latter phenomenon clearly distinguished this antigen from CAA. Further studies showed similarities with respect to stability and solubility, but distinct differences with respect to monosaccharide composition [25,27]. Apart from its presence in urine, M antigen was also demonstrated in patient sera, milk of infected mothers, as well as in sera and urine of animals infected with *Schistosoma mansoni* [25,111]. Independently, Deelder *et al.* (1976) demonstrated a circulating cathodic antigen (CCA) present in serum and urine of infected hamsters [44]. This antigen was localized in epithelial cells of the schistosome gut and detected in excretory and secretory products. It is now generally accepted that M antigen and CCA are identical [46,54]¹. A summary of the characteristics of CCA is given in Table 2.

Apart from these antigens detectable in the circulation of the host, a very early report by Okabe and Tanaka (1958) [91] described an antigen in the urine of patients or experimental animals with schistosomiasis japonica. This antigen appeared to be a heat-labile, easily degradable protein, but it has not been investigated whether the antigen was indeed *Schistosoma*-specific or whether it was *e.g.* a host-derived inflammatory (acute-phase) protein [92].

Ripert *et al.* (1988) described a circulating gut-associated antigen, excreted in the urine of schistosomiasis patients, which was predominantly present in eggs [103]. This antigen showed characteristics similar to those of CCA, such as being excreted in high concentrations in the urine, stability towards protein denaturing agents, sensitivity to periodate, and being localized in the schistosome gut [5,6]. However, CCA is not present in large amounts in the

¹ Like CAA, the acronym CCA is now widely used instead of M antigen, and throughout this thesis we also will use CCA.

eggs, whereas the antigen described by Ripert and Appriou is predominantly an egg antigen [6]. The McAb recognizing this antigen has been investigated in our laboratory for cross-reactions with anti-CAA and anti-CCA McAbs. The recognition and binding patterns in several immunochemical techniques indicated an antigen specificity different from our anti-CAA or anti-CCA McAbs. However, common epitopes might be present on CCA as a few anti-CCA McAbs (also recognizing an egg antigen) showed inhibition of the McAb of Ripert using immunofluorescence assay on adult worm sections (Deelder *et al.*, unpublished results).

Very few functional studies have been performed on the gut-associated antigens. While it is clear that *e.g.* the gut-associated proteases cathepsin B and hemoglobinase are involved in digestive processes, different functions for CAA and CCA have been suggested, but none of these could be experimentally supported. The localization of CCA in the gut epithelium of the adult worm, as well as structural characterization data (molecular heterogeneity, glycoprotein composition, and the presence of O-glycosidic linkages) support the hypothesis that the antigen is a mucin or mucus glycoprotein-like component [27], which protects the gastrodermis of the worm against proteolytic secretions. The observation that the half-life in the schistosome gut of GlcNAc-containing polysaccharides was significantly longer than the half-life of gut secretory proteins also suggests that these carbohydrate structures might function as a protective surface coat [131]. Deelder *et al.* (1989) [48] postulated that CCA and the formation of anti-CCA antibodies may play a role in the parasite's evasion of the immune response of the host. The reasons for this were that many anti-CCA McAbs recognize epitopes of the schistosome egg, and carbohydrate egg antigens are supposed to elicit 'blocking' IgM antibodies which may interfere with the binding of protective IgG antibodies directed against surface antigens of the schistosomulum [19,20,50]. The above described IgM McAb of Appriou *et al.* (1986) directed against a gut-associated antigen similar but not identical to CCA [6], showed an inhibitory effect on immunity after passive transfer in mice [5]. The authors suggested that the McAb blocking activity might interfere with non-specific immune mechanisms. Using several anti-CCA McAbs in passive transfer experiments, however, we could not demonstrate an inhibitory effect on immunity (unpublished observations). Van Egmond *et al.* (1981) [124] showed that purified CCA preparations, as well as a preparation of excretory and secretory antigens, are capable of inducing complement activation. The exact mechanism of this complement activation could not be found.

Likewise, the role of CAA in the physiology of the schistosome remains speculative; perhaps it protects the gastrodermis against digestive enzymes, low pH, or host materials such as antibodies or complement [83,86]. Once in the circulation of the host, this highly negatively charged compound could interfere with the normal surface interactions of the host cells, possibly altering immune

responses or blood clotting processes [86]. A preparation of excretory and secretory antigens containing CAA in relatively large quantities has been shown to interfere with hemostatic processes [72]. Tsang *et al.* (1977) [121,122] described an anticoagulatory activity in a whole worm homogenate of *Schistosoma mansoni*, which is not destroyed by heating the antigen to 100°C for 10 min, suggesting that CAA might be involved. Robertson and Cain (1985) have described the analysis of glycosaminoglycans from *Schistosoma mansoni* and suggested that these structures (including CAA which has a glycosaminoglycan-like monosaccharide composition) might be involved in the prevention of entrapment of the parasites by the host's blood-clotting process [104].

Both CAA and CCA have been described to be involved in pathology as CAA- and CCA-containing immune complexes have been found to be deposited in the kidney and in the liver [26,52,64,65]. It has been reported that schistosomal-specific nephropathy exists and can lead to end-stage renal disease, with CAA and CCA as major responsible antigens [117,118]. This schistosomal-specific nephropathy, however, does not show any remission after anti-schistosomal treatment [119], suggesting that also other mechanisms are involved in the induction of pathology, as has already been described earlier [126]. In schistosomiasis haematobium an association between the disease and bladder cancer has been described [70,112,120], but it is unlikely that antigens or immune complexes play a role herein. Other mechanisms have been suggested such as urothelium chromosomal damage caused by *S. haematobium* infection [106].

In conclusion, the gut-associated antigens of *Schistosoma* constitute an immunologically and physiologically important group of antigens. Analysis of two major antigens, CAA and CCA, which are the targets in two recently developed immunodiagnostic assays for schistosomiasis, indicated that the important epitopes are carbohydrates. Therefore, a major theme of this thesis will be the molecular characterization of these carbohydrate structures. Based on the results, the role or effect of these antigens will be investigated in relation to the immune system of the host.

References

1. Abdel-Hafez SK, Phillips SM, Zodda DM. *Schistosoma mansoni*: detection and characterization of antigens and antigenemia by inhibition enzyme-linked immunosorbent assay (IELISA). *Experimental Parasitology* 1983; 55:219-232.
2. Abe T, Colley DG. Modulation of *Schistosoma mansoni* egg-induced granuloma formation. III. Evidence for an anti-idiotypic, I-J-positive, I-J-restricted, soluble T suppressor factor. *Journal of Immunology* 1984; 132: 2084-2088.
3. Agnew AM, Lucas SB, Doenhoff MJ. The host-parasite relationship of *Schistosoma haematobium* in CBA mice. *Parasitology* 1988; 97:403-424.

4. Andrade ZA, Sadigursky M. Immunofluorescence studies of schistosome structures which share determinants with circulating schistosome antigens. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1978; 72:316–317.
5. Appriou M, Ben Younes R, Tribouley-Duret J, Tribouley J. Étude par la réaction d'immunofluorescence des anticorps dirigés contre les antigènes de l'épithélium intestinal de *Schistosoma mansoni*. IV. Étude du pouvoir bloquant sur l'immunité d'un anticorps monoclonal de classe IgM. *Annales de Parasitologie Humaine et Comparée* 1989; 64:456–468.
6. Appriou M, Tribouley-Duret J, Tribouley J. Étude par la réaction d'immunofluorescence des anticorps dirigés contre les antigènes de l'épithélium intestinal de *Schistosoma mansoni*. III. Étude de la réactivité d'un anticorps monoclonal. *Annales de Parasitologie Humaine et Comparée* 1986; 61:435–446.
7. Aune TM, Freeman GL, Colley DG. Production of the lymphokine soluble immune response suppressor (SIRS) during chronic experimental schistosomiasis mansoni. *Journal of Immunology* 1985; 135:2768–2771.
8. Barsoum IS, Bogitsh BJ, Colley DG. Detection of *Schistosoma mansoni* circulating cathodic antigen for evaluation of resistance induced by irradiated cercariae. *Journal of Parasitology* 1992; 78:681–686.
9. Basch PF. *Schistosomes. Development, reproduction, and host relations*. Oxford University Press, Oxford, 1991.
10. Beisler GK, Matsuda H, Nakao M, Tanaka H. Variations of titers of immunofluorescent antibody against cercaria, adult and egg antigens developed in rabbits infected with *Schistosoma japonicum* before and after treatment with praziquantel. *Japanese Journal of Experimental Medicine* 1984; 54:17–22.
11. Bentley AG, Carlisle AS, Phillips SM. Ultrastructural analysis of the cellular response to *Schistosoma mansoni*. II. Inflammatory response in rodent skin. *American Journal of Tropical Medicine and Hygiene* 1981; 30:815–824.
12. Berggren WL, Weller TH. Immunoelectrophoretic demonstration of specific circulating antigen in animals infected with *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1967; 16:606–612.
13. Blanton RE, Matsumoto Y, Peters PA, El Ibiary S, King CH, Mahmoud AA, Aikawa . Ultrastructural localization of a protective 68,000 molecular weight antigen in *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1991; 45:112–120.
14. Blok J, Franssen JAM, Ginsel LA. Mini-review: turnover of brushborder glycoproteins in human intestinal absorptive cells: do lysosomes have a regulatory function? *Cell Biology International Reports* 1984; 8:993–1014.
15. Bogitsh BJ. Cytochemical and biochemical observations on the digestive tract of digenic trematodes. XI. *Megalodiscus temperatus*. *Experimental Parasitology* 1972; 32:244–260.
16. Bogitsh BJ. Observations on digestion in schistosomes or "Blood and Guts". *Transactions of the American Microscopical Society* 1989; 108:1–5.
17. Bogitsh BJ, Dresden MH. Fluorescent histochemistry of acid proteases in adult *Schistosoma mansoni* and *Schistosoma japonicum*. *Journal of Parasitology* 1983; 69:106–110.
18. Borojevic R, Santos da Silva C, Carvalho EA. Chronic schistosomiasis mansoni: splenic myelopoiesis and inhibition of neutrophil granulocytopenia mediated by the sera of infected patients. *Journal of Infectious Diseases* 1983; 148:422–426.
19. Butterworth AE, Bensted-Smith R, Capron A, Capron M, Dalton PR, Dunne DW, Grzych J-M, Kariuki HC, Khalife J, Koech DK, Mugambi M, Ouma JH, Arap Siogok TK, Sturrock RF. Immunity in human schistosomiasis mansoni: prevention by blocking antibodies of the expression of immunity in young children. *Parasitology* 1987; 94:281–300.
20. Butterworth AE, Dunne DW, Fulford AJC, Capron M, Khalife J, Capron A, Koech DK, Ouma JH, Sturrock RF. Immunity in human schistosomiasis mansoni: cross-reactive IgM and IgG2 anti-carbohydrate antibodies block the expression of immunity. *Biochimie* 1988; 70:1053–1063.
21. Butterworth AE, Richardson BA. Factors affecting the levels of antibody- and complement-dependent eosinophil-mediated damage to schistosomes of *Schistosoma mansoni* in vitro. *Parasite Immunology* 1985; 7:119–131.
22. Camus D, Nosseir A, Mazingue C, Capron A. Immunoregulation by *Schistosoma mansoni*. *Immunopharmacology* 1981; 3:193–204.
23. Capron A, Dessaint JP. Molecular Basis of Host-Parasite Relationship – Towards the Definition of Protective Antigens. *Immunology Reviews* 1989; 112:27–48.
24. Carlier Y, Bout D, Bina JC, Camus D, Figueiredo JFM, Capron A. Immunological studies in human schistosomiasis. I. Parasitic

- antigen in urine. *American Journal of Tropical Medicine and Hygiene* 1975; 24:949–954.
25. Carlier Y, Bout D, Capron A. Further studies on the circulating M antigen in human and experimental *Schistosoma mansoni* infections. *Annales de l'Immunologie (Institut Pasteur)* 1978; 129C:811–818.
 26. Carlier Y, Bout D, Capron A. Detection of *Schistosoma mansoni* M antigen in circulating immune-complexes and in kidneys of infected hamsters. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1980; 74:534–538.
 27. Carlier Y, Bout D, Strecker G, Debray H, Capron A. Purification, immunochemical, and biological characterization of the *Schistosoma* circulating M antigen. *Journal of Immunology* 1980; 124:2442–2450.
 28. Caulfield JP, Chiang Ch-P. How does the schistosome evade host defenses? *Gastroenterology* 1990; 98:1712–1713.
 29. Caulfield JP, Cianci CM. Human erythrocytes adhering to schistosomula of *Schistosoma mansoni* lyse and fail to transfer membrane components to the parasite. *Journal of Cell Biology* 1985; 101:158–166.
 30. Caulfield JP, Hein A, Moser G, Sher A. Light and electron microscopic appearance of rat peritoneal mast cells adhering to schistosomula of *Schistosoma mansoni* by means of complement or antibody. *Journal of Parasitology* 1981; 67:776–783.
 31. Caulfield JP, Lenzi HL, Elsas P, Dessein AJ. Ultrastructure of the attack of eosinophils stimulated by blood mononuclear cell products on schistosomula of *Schistosoma mansoni*. *American Journal of Pathology* 1985; 120:380–390.
 32. Chappell CL, Dresden MH. *Schistosoma mansoni*: proteinase activity of "hemoglobinase" from the digestive tract of adult worms. *Experimental Parasitology* 1986; 61:160–167.
 33. Chappell CL, Dresden MH. Antibody response to a purified parasite proteinase (SMw32) in *Schistosoma mansoni* infected mice. *American Journal of Tropical Medicine and Hygiene* 1988; 39:66–73.
 34. Cheever AW. Comparison of pathologic changes in mammalian hosts infected with *Schistosoma mansoni*, *S. japonicum* and *S. haematobium*. *Memorias Do Instituto Oswaldo Cruz* 1987; 82 Suppl. 4:39–45.
 35. Clegg JA, Smithers SR, Terry RJ. Acquisition of human antigens by *Schistosoma mansoni* during cultivation in vitro. *Nature (London)* 1971; 232:653–654.
 36. Coulson PS, Wilson RA. Examination of the mechanisms of pulmonary phase resistance to *Schistosoma mansoni* in vaccinated mice. *American Journal of Tropical Medicine and Hygiene* 1988; 38:529–539.
 37. Crabtree JE, Wilson RA. *Schistosoma mansoni*: cellular reactions to challenge infections in the cheek pouch skin of chronically infected Chinese hamsters. *Parasitology* 1984; 89:59–69.
 38. Davern KM, Tiu WU, Samaras N, Gearing DP, Hall BE, Garcia EG, Mitchell GF. *Schistosoma japonicum*: monoclonal antibodies to the Mr 26,000 schistosome glutathione S-transferase (Sj26) in an assay for circulating antigen in infected individuals. *Experimental Parasitology* 1990; 70:293–304.
 39. De Jonge N, Kreamsner PG, Krijger FW, Schommer G, Fillié YE, Kornelis D, Van Zeyl RJM, Van Dam GJ, Feldmeier H, Deelder AM. Detection of the schistosome circulating cathodic antigen by enzyme immunoassay using biotinylated monoclonal antibodies. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1990; 84:815–818.
 40. De Jonge N, Schommer G, Krijger FW, Feldmeier H, Zwingenberger K, Steiner A, Bienzle U, Deelder AM. Presence of circulating anodic antigen in serum of *Schistosoma intercalatum*-infected patients from Gabon. *Acta Tropica (Basel)* 1989; 46:115–120.
 41. De Water R, Fransen JAM, Deelder AM. Ultrastructural localization of the circulating cathodic antigen in the digestive tract of various life-cycle stages of *Schistosoma mansoni*. *Zeitschrift für Parasitenkunde* 1986; 72:635–646.
 42. De Water R, Fransen JAM, Deelder AM. Ultrastructural localization of the circulating anodic antigen in the digestive tract of *Schistosoma mansoni* using monoclonal antibodies in an immunogold labeling procedure. *American Journal of Tropical Medicine and Hygiene* 1986; 35:549–558.
 43. Deelder AM, El-Dosoky I, Van Marck EAE, Qian ZL. Immunofluorescent localization of *Schistosoma mansoni* circulating cathodic antigen in tissues of infected mice using monoclonal antibody. *Zeitschrift für Parasitenkunde* 1985; 71:317–323.
 44. Deelder AM, Klappe HTM, Van den Aardweg GJM, Van Meerbeke EHEM. *Schistosoma mansoni*: demonstration of two circulating antigens in infected hamsters. *Experimental Parasitology* 1976; 40:189–197.
 45. Deelder AM, Kornelis D. Immunodiagnosis of recently acquired *Schistosoma mansoni* infection. A comparison of various immunological techniques. *Tropical and Geographical Medicine* 1981; 33:36–41.
 46. Deelder AM, Kornelis D, Van Marck EAE, Eveleigh PC, Van Egmond JG. *Schistosoma*

- mansoni*: characterization of two circulating polysaccharide antigens and the immunological response to these antigens in mouse, hamster, and human infections. *Experimental Parasitology* 1980; 50:16–32.
47. Deelder AM, Van den Berge W. Detection of antibodies against circulating cathodic antigen of *Schistosoma mansoni* using the enzyme-linked immunosorbent assay. *Zeitschrift für Parasitenkunde* 1981; 64:179–186.
 48. Deelder AM, Van Zeyl RJM, Fillié YE, Rotmans JP, Duchenne W. Recognition of gut-associated antigens by immunoglobulin M in the indirect fluorescent antibody test for schistosomiasis mansoni. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1989; 83:364–367.
 49. Dessein AJ, Samuelson JC, Butterworth AE, Hogan M, Sherry BA, Vadas MA, David JR. Immune evasion by *Schistosoma mansoni*: loss of susceptibility to antibody or complement-dependent eosinophil attack by schistosomula cultured in medium free of macromolecules. *Parasitology* 1981; 82:357–374.
 50. Dunne DW. Schistosome carbohydrates. *Parasitology Today* 1990; 6:45–48.
 51. Dunne DW, Bickle QD, Butterworth AE, Richardson BA. The blocking of human antibody-dependent, eosinophil-mediated killing of *Schistosoma mansoni* schistosomula by monoclonal antibodies which cross-react with a polysaccharide-containing egg antigen. *Parasitology* 1987; 94:269–280.
 52. El-Dosoky I, Van Marck EAE, Deelder AM. Presence of *Schistosoma mansoni* antigens in liver, spleen and kidney of infected mice: a sequential study. *Zeitschrift für Parasitenkunde* 1984; 70:491–497.
 53. Evengård B, Hammarström L, Smith CIE, Linder E. Early antibody responses in human schistosomiasis. *Clinical and Experimental Immunology* 1990; 80:69–76.
 54. Feldmeier H. Diagnosis. In: Jordan P, Webbe G, Sturrock RF, eds. *Human schistosomiasis*. CAB International, Wallingford, 1993: 271–303.
 55. Goddard MJ, Jordan P. On the longevity of *Schistosoma mansoni* in man on St. Lucia, West Indies. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1980; 74:185–191.
 56. Golan DE, Brown CS, Cianci CM, Furlong ST, Caulfield JP. Schistosomula of *Schistosoma mansoni* use lysophosphatidylcholine to lyse adherent human red blood cells and immobilize red cell membrane components. *Journal of Cell Biology* 1986; 103:819–828.
 57. Gold R, Rosen FS, Weller TH. A specific circulating antigen in hamsters infected with *Schistosoma mansoni*. Detection of antigen in serum and urine, and correlation between antigenic concentration and worm burden. *American Journal of Tropical Medicine and Hygiene* 1969; 18:545–552.
 58. Goldring OL, Clegg JA, Smithers SR, Terry RJ. Acquisition of human blood group antigens by *Schistosoma mansoni*. *Clinical and Experimental Immunology* 1976; 26:181–187.
 59. Harris AR, Russell RJ, Charters AD. A review of schistosomiasis in immigrants in Western Australia, demonstrating the unusual longevity of *Schistosoma mansoni*. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1984; 78:385–388.
 60. Hassan MM, Badawi MA, Strand M. Circulating schistosomal antigen in diagnosis and assessment of cure in individuals infected with *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1992; 46:737–744.
 61. Hayunga EG, Mollegard I, Duncan JF, Sumner MP, Stek Jr M, Hunter Jr KW. Development of circulating antigen assay for rapid detection of acute schistosomiasis. *Lancet* 1986; 2:716–718.
 62. Hornstein L, Lederer G, Schechter J, Greenberg Z, Boem R, Bilguray B, Giladi L, Hamburger J. Persistent *Schistosoma mansoni* infection in Yemeni immigrants to Israel. *Israel Journal of Medical Sciences* 1990; 26:386–389.
 63. Horta MFM, Ramalho-Pinto FJ. Role of human Decay-accelerating factor in the evasion of *Schistosoma mansoni* from the complement-killing in vitro. *Journal of Experimental Medicine* 1991; 174: 1399–1406.
 64. Hoshino-Shimizu S, De Brito T, Kanamura HY, Canto AL, Silva AO, Campos AR, Penna DO, Da Silva LC. Human schistosomiasis: *Schistosoma mansoni* antigen detection in renal glomeruli. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1977; 70:492–496.
 65. Houba V. Experimental renal disease due to schistosomiasis. *Kidney International* 1979; 16:30–43.
 66. Houba V, Koech DK, Sturrock RF, Butterworth AE, Kusel JR, Mahmoud AA. Soluble antigens and antibodies in sera from baboons infected with *Schistosoma mansoni*. *Journal of Immunology* 1976; 117:705–707.
 67. Kestens L, Mangelschots K, Van Marck EAE, Gigase PLJ, Deelder AM. *Schistosoma mansoni*: impaired clearance of model immune complexes consisting of circulating anodic antigen and monoclonal IgG1 in



- infected mice. *Parasitology Research* 1988; 74:356–362.
68. Kestens L, Mangelschots K, Van Marck EAE, Gigase PLJ, Deelder AM. Clearance of artificial immune complexes consisting of circulating cathodic antigen and monoclonal antibodies in *Schistosoma mansoni* infected mice. *Annals de la Société belge de Médecine Tropicale* 1988; 68:241–254.
69. Khalife J, Capron M, Capron A, Grzych J–M, Butterworth AE, Dunne DW, Ouma JH. Immunity in human schistosomiasis mansoni. Regulation of protective immune mechanisms by IgM blocking antibodies. *Journal of Experimental Medicine* 1986; 164:1626–1640.
70. Kitinya JN, Lauren PA, Eshleman LJ, Paljarvi L, Tanaka K. The incidence of squamous and transitional cell carcinomas of the urinary bladder in northern Tanzania in areas of high and low levels of endemic *Schistosoma haematobium* infection. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1986; 80:935–939.
71. Klinkert MQ, Felleisen R, Link G, Ruppel A, Beck E. Primary structures of Sm31/32 diagnostic proteins of *Schistosoma mansoni* and their identification as proteases. *Molecular and Biochemical Parasitology* 1989; 33:113–122.
72. Kluff C, Trumpi–Kalshoven MM, Deelder AM. Factor XII–independent activator generation in human plasma. In: Davidson JF, Cèpelák V, Samama M, Desnoyers PC, eds. *Progress in Chemical Fibrinolysis and Thrombolysis*, Vol IV. Churchill Livingstone, Edinburgh, 1979:362–367.
73. Kremsner PG, De Jonge N, Simarro PP, Mühlischlegel F, Mir M, Sima FO, Feldmeier H, Bienzle U, Deelder AM. Quantitative determination of circulating anodic and cathodic antigens in serum and urine of individuals infected with *Schistosoma intercalatum*. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1993; 87:167–169.
74. Kruger FJ, Joubert PH. Scanning electron microscopical observations on the shedding of the tegument of adult *Schistosoma mattheei*. *International Journal for Parasitology* 1990; 20:965–967.
75. Lennarz W. Overview: Role of intracellular membrane systems in glycosylation of proteins. In: Fleischer S, Fleischer B, eds. *Methods in Enzymology*, Vol. 98. Academic Press, New York, 1983:91–97.
76. Li YL, Song WJ, Han JJ, Ruppel A. Detection of *Schistosoma japonicum* antigen (sj31/32) in sera of chinese patients using a sandwich ELISA based on monoclonal antibody. *Tropical Medicine and Parasitology* 1994; 45:115–118.
77. Lightowers MW, Rickard MD. Excretory–secretory products of helminth parasites: effects on host immune responses. *Parasitology* 1988; 96:123–166.
78. Mangold BL, Dean DA, Coulson PS, Wilson RA. Site requirements and kinetics of immune–dependent elimination of intravascularly administered lung stage schistosomula in mice immunized with highly irradiated cercariae of *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1986; 35:332–344.
79. McLaren DJ, Smithers SR. *Schistosoma mansoni*: challenge attrition during the lung phase of migration in vaccinated and serum–protected rats. *Experimental Parasitology* 1985; 60:1–9.
80. Mercer JG, Chappell LH. *Schistosoma mansoni*: effect of maintenance in vitro on the physiology and biochemistry of adult worms. *Parasitology* 1985; 90:339–349.
81. Mitchell GF. Glutathione S–transferases – potential components of anti–schistosome vaccines. *Parasitology Today* 1989; 5:34–37.
82. Moser G, Wassom DL, Sher A. Studies of the antibody–dependent killing of schistosomula of *Schistosoma mansoni* employing haptenic target antigens. I. Evidence that the loss in susceptibility to immune damage undergone by developing schistosomula involves a change unrelated to the masking of parasite antigens by host molecules. *Journal of Experimental Medicine* 1980; 152:41–53.
83. Nash TE. Localization of the circulating antigen within the gut of *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1974; 23:1085–1087.
84. Nash TE. Antibody response to a polysaccharide antigen present in the schistosome gut. I. Sensitivity and specificity. *American Journal of Tropical Medicine and Hygiene* 1978; 27:939–943.
85. Nash TE, Deelder AM. Comparison of four schistosome excretory–secretory antigens: phenol–sulfuric test active peak, cathodic circulating antigen, gut–associated proteoglycan, and circulating anodic antigen. *American Journal of Tropical Medicine and Hygiene* 1985; 34:236–241.
86. Nash TE, Nasir UD, Jeanloz RW. Further purification and characterization of a circulating antigen in schistosomiasis. *Journal of Immunology* 1977; 119:1627–1633.
87. Nash TE, Ottesen EA, Cheever AW. Antibody response to a polysaccharide antigen present in the schistosome gut. II. Modulation of antibody response. *American Journal of Tropical Medicine and Hygiene* 1978; 27:944–950.

88. Nash TE, Prescott B, Neva FA. The characteristics of a circulating antigen in schistosomiasis. *Journal of Immunology* 1974; 112:1500-1507.
89. Nour el Din MSA, Kornelis D, Van Zeyl RJM, Deelder AM. Immunologic characterization of two monoclonal antibodies reactive with repetitive carbohydrate epitopes of circulating *Schistosoma mansoni* egg antigen. *American Journal of Tropical Medicine and Hygiene* 1994; 50:487-498.
90. Nour el Din MSA, Nibbeling R, Rotmans JP, Polderman AM, Krijger FW, Deelder AM. Quantitative determination of circulating soluble egg antigen in urine and serum of *Schistosoma mansoni*-infected individuals using a combined two-site enzyme-linked immunosorbent assay. *American Journal of Tropical Medicine and Hygiene* 1994; 50:585-594.
91. Okabe K, Tanaka T. A new urine precipitin reaction for schistosomiasis japonica, a preliminary report. *The Kurume Medical Journal* 1958; 5:45-52.
92. Okabe K, Tanaka T. Urine precipitation reaction for schistosomiasis japonica. *The Kurume Medical Journal* 1961; 8:24-37.
93. Okot-Kotber BM. The development of stage-characteristic immunofluorescence patterns in experimental schistosomiasis in mice. *Annals of Tropical and Medical Parasitology* 1978; 72:255-262.
94. Pearce EJ, Basch PF, Sher A. Evidence that the reduced surface antigenicity of developing *Schistosoma mansoni* schistosomula is due to antigen shedding rather than host molecule acquisition. *Parasite Immunology* 1986; 8:79-94.
95. Pearce EJ, Caspar P, Grzych J-M, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, *Schistosoma mansoni*. *Journal of Experimental Medicine* 1991; 173:159-166.
96. Pearce EJ, Hall BF, Sher A. Host-Specific Evasion of the Alternative Complement Pathway by Schistosomes Correlates with the Presence of a Phospholipase C- Sensitive Surface Molecule Resembling Human Decay Accelerating Factor. *Journal of Immunology* 1990; 144:2751-2756.
97. Pearce EJ, James SL. Post lung-stage schistosomula of *Schistosoma mansoni* exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo. *Parasite Immunology* 1993; 8:513-527.
98. Pearce EJ, Sher A. Functional dichotomy in the CD4+ T cell response to *Schistosoma mansoni*. *Experimental Parasitology* 1991; 73:110-116.
99. Qian ZL, Deelder AM. Circulating antigens in *Schistosoma*-infections. *Acta Leidensia* 1982; 49:71-80.
100. Qian ZL, Deelder AM. *Schistosoma japonicum*: immunological response to circulating polysaccharide antigens in rabbits with a light infection. *Experimental Parasitology* 1983; 55:394-403.
101. Qian ZL, Deelder AM. *Schistosoma japonicum*: immunological characterization and detection of circulating polysaccharide antigens from adult worms. *Experimental Parasitology* 1983; 55:168-178.
102. Remold HG, Mednis A, Hein A, Caulfield JP. Human monocyte-derived macrophages are lysed by schistosomula of *Schistosoma mansoni* and fail to kill the parasite after activation with interferon gamma. *American Journal of Pathology* 1988; 131:146-155.
103. Ripert C, Combe A, Daulouede S, Appriou M, Tribouley-Duret J, Tribouley J, Moyou-Somo R, Same-Ekobo A, Ambassa P. Detection with a monoclonal antibody of an antigen characteristic of the genus *Schistosoma* excreted in the urine. *Tropical Medicine and Parasitology* 1988; 39:131-135.
104. Robertson NP, Cain GD. Isolation and characterization of glycosaminoglycans from *Schistosoma mansoni*. *Comparative Biochemistry and Physiology* 1985; 82B:299-306.
105. Rogers MV, Henkle KJ, Herrmann V, McLaren DJ, Mitchell GF. Evidence that a 16-kilodalton integral membrane protein antigen from *Schistosoma japonicum* adult worms is a type A2 phospholipase. *Infection and Immunity* 1991; 59:1442-1447.
106. Rosin MP, Anwar W. Chromosomal damage in urothelial cells from Egyptians with chronic *Schistosoma haematobium* infections. *International Journal of Cancer* 1992; 50:539-543.
107. Ruppel A, Idris MA, Sulaiman SM, Hilali AM. *Schistosoma mansoni* diagnostic antigens (Sm 31/12): a sero-epidemiological study in the Sudan. *Tropical Medicine and Parasitology* 1990; 41:127-130.
108. Ruppel A, Xing Y, Dell R, Numrich P, Shi YE. *Schistosoma mansoni* and *S. japonicum*: decline of antibodies against diagnostic adult worm antigens (Sm31/32) following praziquantel treatment of mice. *Tropical Medicine and Parasitology* 1991; 42:325-331.
109. Samuelson JC, Caulfield JP. Loss of covalently labeled glycoproteins and glycolipids from the surface of newly transformed schistosomula of *Schistosoma mansoni*. *Journal of Cell Biology* 1982; 94:363-369.

110. Samuelson JC, Caulfield JP, David JR. Schistosomula of *Schistosoma mansoni* clear concanavalin A from their surface by sloughing. *Journal of Cell Biology* 1982; 94:355-362.
111. Santoro F, Borojevic R, Bout D, Tachon P, Bina JC, Capron A. Mother-child relationship in human schistosomiasis mansoni. *American Journal of Tropical Medicine and Hygiene* 1977; 26:1164-1168.
112. Schwartz DA. Helminths in the induction of cancer. II. *Schistosoma haematobium* and bladder cancer. *Tropical and Geographical Medicine* 1981; 33:1-7.
113. Senft AW. Observations on the physiology of the gut of *Schistosoma mansoni*. In: Van den Bossche H, ed. *Biochemistry of parasites and host-parasite relationships*. Elsevier/North Holland Biomedical Press, Amsterdam, 1976:335-342.
114. Sher A. Acquisition of murine major histocompatibility complex gene products by schistosomula of *Schistosoma mansoni*. *Journal of Experimental Medicine* 1978; 148:46-57.
115. Simpson AJG, Smithers SR. Schistosomes: surface, egg and circulating antigens. In: Parkhouse RME, ed. *Current Topics in Microbiology and Immunology*, Vol. 120. Springer-Verlag, Berlin, 1985:205-239.
116. Smith JH, Christie JD. The pathobiology of *Schistosoma haematobium* infection in humans. *Human Pathology* 1986; 17:333-345.
117. Sobh MA, Moustafa FE, El Housseini F, Basta MT, Deelder AM, Ghoniem MA. Schistosomal specific nephropathy leading to end-stage renal failure. *Kidney International* 1987; 31:1006-1011.
118. Sobh MA, Moustafa FE, Sally SM, Deelder AM, Ghoniem MA. Characterisation of kidney lesions in early schistosomal-specific nephropathy. *Nephrology Dialysis Transplantation* 1988; 3:392-398.
119. Sobh MA, Moustafa FE, Sally SM, Deelder AM, Ghoniem MA. Effect of anti-schistosomal treatment on schistosomal-specific nephropathy. *Nephrology Dialysis Transplantation* 1988; 3:744-751.
120. Thomas JE, Bassett MT, Sigola LB, Taylor P. Relationship between bladder cancer incidence, *Schistosoma haematobium* infection, and geographical region in Zimbabwe. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1990; 84:551-553.
121. Tsang VCW, Damian RT. Demonstration and mode of action of an inhibitor for activated Hageman factor (factor XIIa) of the intrinsic blood coagulation pathway from *Schistosoma mansoni*. *Blood* 1977; 49:619-633.
122. Tsang VCW, Hubbard WJ, Damian RT. Coagulation factor XIIa (activated Hageman factor) inhibitor from adult *Schistosoma mansoni*. *American Journal of Tropical Medicine and Hygiene* 1977; 26:243-247.
123. Van der Linden PWG, Koerten HK, Deelder AM. Scanning electron microscopical observations on antigen-antibody coat formation on mechanically transformed *Schistosoma mansoni* schistosomula. *Zeitschrift für Parasitenkunde* 1982; 68:73-80.
124. Van Egmond JG, Deelder AM, Daha MR. *Schistosoma mansoni*: complement activation by antigenic preparations. *Experimental Parasitology* 1981; 51:188-194.
125. Van Helden HPT, Terpstra WJ, Okot-Kotber BM, Eyakuze VM. Are there stage-characteristic immunofluorescence patterns in schistosomiasis? *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1975; 69:309-311.
126. Van Marck EAE, Deelder AM, Gigase PLJ. Effect of partial portal vein ligation on immune glomerular deposits in *Schistosoma mansoni*-infected mice. *British Journal of Experimental Pathology* 1977; 58:412-417.
127. Vermund SH, Bradley DJ, Ruiz-Tiben E. Survival of *Schistosoma mansoni* in the human host: estimates from a community-based prospective study in Puerto Rico. *American Journal of Tropical Medicine and Hygiene* 1983; 32:1040-1048.
128. Warren KS. The pathology, pathobiology and pathogenesis of schistosomiasis. *Nature (London)* 1978; 273:609-612.
129. Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosomiasis mansoni in Yemen in California: duration of infection, presence of disease, therapeutic management. *American Journal of Tropical Medicine and Hygiene* 1974; 23:902-909.
130. Wilkins HA, Blumenthal UJ, Hagan P, Hayes RJ, Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1987; 81:29-35.
131. Wilson RA, Barnes PE. Synthesis of macromolecules by the epithelial surfaces of *Schistosoma mansoni*: an autoradiographic study. *Parasitology* 1979; 78:295-310.
132. Wilson RA, Coulson PS, Dixon B. Migration of the schistosomula of *Schistosoma mansoni* in mice vaccinated with radiation-attenuated cercariae, and normal mice: an attempt to identify the timing and site of parasite death. *Parasitology* 1986; 92:101-116.